Sandoz Benefits From Betting Big On Biosimilars
Biosimilars Sales Up 26% In Q4; Multiple Portfolio And Pipeline Opportunities Outlined
Sandoz’s biosimilars business was a big earner for the company in 2023. During the firm’s Q4 results call, CEO Richard Saynor provided a detailed breakdown of key products in the biosimilars portfolio and pipeline, as he highlighted sales growth of 26% in the most recent quarter.
